Company news
Thiogenesis Therapeutics Corp (TSXV:TTI) news
Thiogenesis Therapeutics Corp news releases on 6ix. Latest, Sep 21, 2026: Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders…
Press releases & updates
Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update
September 21, 2026
Thiogenesis Engages Brisco Capital for Investor Relations
September 3, 2026
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome
July 13, 2026
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
June 17, 2026
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
June 3, 2026
Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
June 1, 2026
Thiogenesis Announces Non-Brokered Private Placement
May 11, 2026
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
April 16, 2026
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
February 2, 2026
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
January 23, 2026
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
January 13, 2026
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
January 5, 2026
Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th
December 9, 2025
Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th
December 9, 2025
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
December 9, 2025
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
November 24, 2025
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
November 4, 2025
Thiogenesis Announces Extension to Investor Relations Agreement
October 3, 2025
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
September 11, 2025
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares
August 14, 2025
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares
August 1, 2025
Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares
July 29, 2025
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
July 17, 2025
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
June 25, 2025
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
June 20, 2025
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
June 17, 2025
Thiogenesis Announces Grant of Stock Options
June 12, 2025
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum
June 11, 2025
Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")
May 14, 2025
Thiogenesis Announces European Consulting and Investor Relations Agreement
February 20, 2025
Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
February 12, 2025
OTC Markets Group Welcomes Thiogenesis Therapeutics, Corp. to OTCQX
February 12, 2025
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
January 27, 2025
Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease
December 10, 2024
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
November 28, 2024
Thiogenesis Announces Important Core Patent Allowed in Europe
November 4, 2024
Thiogenesis Announces Investor Relations Engagement
September 27, 2024
Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium
September 17, 2024
Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program
August 20, 2024
Thiogenesis Announces Leigh Syndrome Clinical Program
July 18, 2024
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
March 25, 2024
TSX Venture Exchange Stock Maintenance Bulletins
December 29, 2023
Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement
December 20, 2023
Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation
December 18, 2023
Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium
December 4, 2023
Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board
November 27, 2023
Thiogenesis Therapeutics Reports on Full Year 2022 Financial Results and Provides Corporate Update
May 10, 2023
Thiogenesis Announces Stock Option Grants
December 9, 2022
Thiogenesis Announces Closing of Oversubscribed $5.3 Million Non-Brokered Private Placement
November 21, 2022
Thiogenesis Announces Increase in Offering Size for Non-Brokered Private Placement of Common Shares
November 2, 2022